HOUSTON & HONG KONG--(BUSINESS WIRE)--PLx Pharma Inc, a Houston based pharmaceutical company developing gastrointestinal (GI) safer drugs has licensed to Lee’s Pharmaceutical Holdings Limited (Lee’s Pharma) the rights to register and commercialize in China, Hong Kong and Macau the PL2200 Aspirin, a GI safer aspirin product currently in development in the US, for prevention of cardiovascular diseases. Cardiovascular is one of the focus areas of Lee’s Pharma. Currently, Lee’s Pharma has 10 products either launched or under development for cardiovascular diseases such as pulmonary arterial hypertension, hypertension, heart failure and acute coronary disease.
